Home » Healthcare » Mexico Chronic Pain Market

Mexico Chronic Pain Market By Product (Drugs, Devices); By Indication (Neuropathic Pain, Arthritis Pain, Chronic Back Pain, Cancer Pain, Migraine, Fibromyalgia, Others); By Application (Musculoskeletal, Neuropathy, Oncology, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Mexico Chronic Pain Market Size 2024	USD 2,265.54 million
Mexico Chronic Pain Market, CAGR	3.79%
Mexico Chronic Pain Market Size 2032	USD 3,273.41 million

Market Overview

The chronic pain market in Mexico is projected to grow from USD 2,265.54 million in 2023 to USD 3,273.41 million by 2032, reflecting a compound annual growth rate (CAGR) of 3.97%.

The Mexico chronic pain market is driven by the increasing prevalence of conditions such as osteoarthritis, neuropathy, and cancer-related pain, coupled with the aging population. Growing awareness of pain management therapies and advancements in pain treatment options, including pharmaceutical and non-pharmaceutical interventions, further contribute to market expansion. Additionally, the rising adoption of telemedicine and digital health solutions has enhanced access to pain management services, improving patient outcomes. Government initiatives aimed at improving healthcare infrastructure and providing better pain management treatments are also expected to support market growth. On the trends front, there is a shift towards personalized pain management, with an emphasis on precision medicine and tailored therapies. The integration of artificial intelligence in pain management research and the development of novel drug delivery systems are also transforming the market. These factors, combined with ongoing research and innovation, are likely to drive sustained growth in Mexico’s chronic pain sector.

The geographical analysis of the chronic pain market in Mexico reveals a significant concentration of healthcare services in key urban areas, particularly Mexico City, Monterrey, and Guadalajara. These regions are home to advanced healthcare facilities, specialized pain management centers, and a high prevalence of chronic pain conditions. The market is driven by a combination of aging populations, sedentary lifestyles, and rising healthcare access. Key players in the Mexican chronic pain market include major pharmaceutical companies such as Abbott Laboratories, Pfizer Inc., Eli Lilly & Company, and Merck & Co. Inc., which offer a wide range of pain management therapies. Additionally, companies like Cara Therapeutics and F. Hoffmann-La Roche AG play a role in the development of innovative treatments. Local and international players are working to expand access to effective pain management solutions, addressing the growing demand across urban and rural areas of the country.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Insights

The Mexico chronic pain market was valued at USD 2,265.54 million in 2023 and is projected to reach USD 3,273.41 million by 2032, growing at a CAGR of 3.97%.
Increasing prevalence of chronic conditions, including arthritis and neuropathy, is a key driver of market growth.
The aging population and sedentary lifestyles are contributing significantly to the rise in chronic pain cases.
Growing awareness of chronic pain management options and improved access to healthcare are driving market demand.
Limited awareness of chronic pain, especially in rural areas, remains a major challenge in market growth.
Regulatory hurdles and the stigma associated with opioid use create barriers to effective pain management.
The market is concentrated in major regions such as Mexico City, Monterrey, and Guadalajara, where healthcare infrastructure is more developed.

Market Drivers

Increasing Prevalence of Chronic Diseases

The growing prevalence of chronic diseases in Mexico is a significant driver of the chronic pain market. The aging population is contributing to an increase in conditions like arthritis, fibromyalgia, and neuropathy, all of which are linked to chronic pain. For instance, the prevalence of chronic diseases such as diabetes and hypertension is high among older adults in Mexico. Additionally, modern sedentary lifestyles, with reduced physical activity, are leading to a rise in musculoskeletal disorders and other chronic pain conditions. The rising incidence of obesity further exacerbates this issue, as obesity is often associated with joint pain, back pain, and other musculoskeletal problems, creating a higher demand for pain management solutions.

Government Initiatives and Policy Changes

Government initiatives and policy changes are playing a critical role in the growth of the chronic pain market. Regulatory reforms designed to streamline the approval process for new pain management therapies are making innovative treatments more accessible to the population. For instance, the Mexican government has launched initiatives to improve access to pain management therapies and raise awareness about chronic pain. Favorable reimbursement policies for chronic pain treatments are encouraging patients to seek care and ensuring that more individuals can afford necessary therapies. Public health campaigns are also raising awareness about the importance of effective pain management, further driving demand for chronic pain treatments in Mexico.

Growing Awareness and Demand for Effective Pain Management

As healthcare access improves across Mexico, there is a growing awareness of chronic pain and the available management options. Patients are becoming more informed about their conditions and are increasingly seeking effective treatments to manage pain. This awareness is further driven by the widespread use of social media and online resources, where individuals can find information about chronic pain management options. As a result, patients are more empowered and actively engaged in their healthcare decisions, leading to an increased demand for comprehensive pain management solutions.

Advancements in Pain Management Therapies

Advancements in pain management therapies are contributing to market growth by providing more effective and less invasive treatment options. The development of new pain medications and therapies is improving treatment outcomes for individuals suffering from chronic pain. Additionally, the rise of minimally invasive procedures, such as injections and laser treatments, is offering patients more convenient and less painful alternatives to traditional surgery. Digital health solutions, including telemedicine and remote monitoring tools, are further enhancing access to pain management services, enabling patients to receive care in the comfort of their homes.

Market Trends

Rising Prevalence of Chronic Conditions and Growing Awareness

Mexico is experiencing a rise in the prevalence of chronic pain conditions, driven by factors such as an aging population and increasingly sedentary lifestyles. As the population ages, the incidence of age-related conditions like arthritis, fibromyalgia, and neuropathy is on the rise, contributing to a higher demand for chronic pain management solutions. At the same time, modern lifestyles, characterized by reduced physical activity and poor posture, are leading to an increase in chronic pain, particularly among younger demographics. For instance, public health campaigns and online resources are helping to raise awareness about chronic pain and its management. The combination of these factors is placing significant pressure on the healthcare system to address the growing need for pain management. Parallel to this, the growing awareness about chronic pain and its management is driving demand for effective treatments. With improved access to healthcare services, individuals are becoming more informed about available options for pain management. Patients are increasingly proactive in seeking solutions, empowered by the information available through social media and online platforms. These resources have helped raise awareness about the importance of timely and effective pain management, further pushing the demand for innovative pain relief solutions. As people become more educated and proactive about their health, the need for comprehensive treatment plans is expanding, fostering growth in the chronic pain management market.

Advancements in Pain Management Therapies and Government Initiatives

The development of new pain management therapies and advancements in treatment technologies are transforming the market. The pharmaceutical industry continues to introduce innovative pain medications that offer more effective and targeted relief for chronic pain sufferers. In addition to drug development, there has been significant progress in minimally invasive procedures, such as injections and radiofrequency treatments, which offer less disruptive, patient-friendly alternatives to traditional surgeries. Digital health solutions, including telemedicine and mobile health apps, have also emerged as valuable tools for improving access to pain management services, especially in remote or underserved areas. These advancements are making pain management more effective, accessible, and convenient for patients.
In parallel, government initiatives and policy changes are helping to drive the chronic pain market forward. Regulatory reforms are streamlining the approval processes for new treatments, making it easier for innovative therapies to reach the market. Moreover, favorable reimbursement policies are ensuring that chronic pain treatments are more accessible to a broader segment of the population. Public health campaigns focusing on pain awareness and management are also contributing to increased demand for pain management services. These efforts from both the government and healthcare providers are creating an environment conducive to the growth of the chronic pain market, helping to improve patient outcomes and expand access to necessary therapies.

Market Challenges Analysis

Limited Awareness, Stigma, and Inequitable Access to Healthcare

One of the major challenges in Mexico’s chronic pain market is the limited awareness of pain management, particularly in rural areas. Many individuals in these regions have a poor understanding of chronic pain conditions and the available treatment options, which leads to delays in seeking proper care. This lack of education, coupled with societal stigma surrounding pain, further exacerbates the problem. In some communities, individuals may feel ashamed or reluctant to seek help due to the cultural perception that pain is something that should be endured in silence. This stigma results in underdiagnosis and undertreatment, leaving many patients suffering without access to effective therapies. In addition to awareness and stigma, there are significant disparities in healthcare access. For instance, around 5 million Mexicans have limited access to care, and approximately 2% of the population lives more than two hours away from a medical facility. Geographic and financial barriers restrict many people, particularly in rural areas, from accessing specialized pain management services. The unequal distribution of healthcare resources, including pain management specialists, limits treatment options for people living outside major cities. Furthermore, high treatment costs and a lack of comprehensive insurance coverage exacerbate this issue, preventing many from obtaining the care they need. These challenges highlight the critical need for greater access to pain management solutions across all regions, especially for vulnerable populations who are most affected by chronic pain.

Regulatory Hurdles, Healthcare Professional Training, and Cultural Barriers

The chronic pain market in Mexico is also hindered by regulatory and policy challenges that complicate the introduction of new treatments. The country’s complex regulatory environment can cause delays in the approval and distribution of innovative pain management therapies, restricting patient access to newer and potentially more effective options. Additionally, there are significant barriers to reimbursement for non-traditional pain management therapies, which further limits the availability of alternative treatment options. A major concern has been the stigma and restrictions surrounding opioid use, driven by the fear of misuse and addiction. These regulations, though aimed at controlling the opioid crisis, can limit access to necessary pain medications for patients who require them for effective pain relief. For example, the Latin American Pain Society (LAPS) promotes pain medicine education and provides hands-on training courses to advance the clinical practice of interventional pain throughout Latin America. Moreover, there is a need for greater healthcare professional training and education in pain management. Many healthcare providers, especially in primary care settings, lack the specialized training needed to effectively manage chronic pain. This gap in knowledge can lead to suboptimal treatment, as providers may not be familiar with the latest evidence-based approaches. Some healthcare professionals also continue to follow outdated pain management practices, which can hinder the adoption of newer, more effective methods. Cultural factors also play a role, as traditional beliefs about pain and treatment can influence patient expectations and adherence to treatment plans.

Market Opportunities

Expansion of Telemedicine and Digital Health Solutions

One of the key opportunities in Mexico’s chronic pain market lies in the expansion of telemedicine and digital health solutions. With growing access to the internet and mobile devices, digital platforms are becoming increasingly popular for managing chronic pain, especially in rural and underserved areas. Telemedicine allows patients to consult with pain management specialists remotely, improving access to care without the need for travel. This can significantly reduce healthcare disparities across the country, providing patients in remote regions with better access to timely treatment. Additionally, digital health tools such as mobile apps, pain tracking devices, and virtual rehabilitation programs offer patients the ability to manage their conditions more effectively at home. The integration of these technologies into traditional pain management systems presents an excellent opportunity to enhance patient outcomes and streamline healthcare delivery in Mexico.

Development of Personalized Pain Management Therapies

Another significant market opportunity lies in the development of personalized pain management therapies. As healthcare providers shift towards more individualized care, there is growing potential for precision medicine in treating chronic pain. Advancements in genomics, biotechnology, and data analytics offer the opportunity to tailor treatments to the specific needs of patients, improving treatment efficacy and minimizing side effects. This approach can be particularly beneficial for patients with complex or multifactorial chronic pain conditions, such as neuropathic pain or fibromyalgia. The Mexican government’s focus on improving healthcare access and the rise of private health insurance are creating an environment conducive to the adoption of these personalized therapies. Furthermore, ongoing research and innovation in pain management treatments, including novel drug therapies and non-invasive procedures, provide additional avenues for market growth and innovation in the coming years.

Market Segmentation Analysis:

By Indication:

The Mexico chronic pain market is primarily segmented by the type of pain experienced by patients, with major categories including neuropathic pain, arthritis pain, chronic back pain, cancer pain, and migraines. Neuropathic pain, often caused by nerve damage or conditions like diabetes and multiple sclerosis, is a significant contributor to chronic pain cases in Mexico. Arthritis pain, driven by aging populations and increasing obesity rates, is another leading segment, particularly among older adults. Chronic back pain, a result of sedentary lifestyles and poor posture, remains prevalent, contributing to high healthcare utilization. Cancer pain, resulting from tumors and treatment side effects, represents a critical segment in the pain management market, with a growing patient base due to an increasing cancer incidence. Additionally, migraines are a widespread condition, often leading to chronic pain for many individuals, impacting their quality of life and workforce productivity. Each of these indications presents unique challenges and opportunities for tailored pain management solutions.

By Drug Class:

The chronic pain market in Mexico is also segmented by drug class, with key categories including opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and other emerging drug classes. Opioids, often used for severe pain relief, are widely prescribed but face growing regulatory scrutiny due to concerns over addiction and misuse. NSAIDs are commonly used for conditions like arthritis and chronic back pain, providing effective relief with fewer side effects than opioids. Anticonvulsants, initially developed for seizure disorders, have proven effective for treating neuropathic pain, representing an important segment for chronic pain management. Antidepressants, particularly tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors, are also used to treat chronic pain, especially in neuropathic conditions. Lastly, the development of new drug classes, such as biologics or novel non-opioid treatments, presents emerging opportunities in the chronic pain market, addressing gaps left by traditional pain medications. The segmentation by drug class allows for diverse treatment options, catering to various patient needs and pain conditions.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Segments:

Based on Indication:

Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer Pain
Migraine

Based on Drug Class:

Opioids
Non-Steroidal
Anticonvulsants
Antidepressants
Drug Class 5

Based on Application:

Musculoskeletal
Neuropathy
Oncology
Others

Based on Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

Based on the Geography:

Mexico City
Monterrey
Guadalajara

Regional Analysis

Mexico City

Mexico City, the capital and largest metropolitan area in the country, dominates the chronic pain market with the largest market share. The city is home to a substantial portion of the country’s healthcare infrastructure, including specialized pain management centers, research institutions, and a high concentration of healthcare professionals. This makes Mexico City a key hub for the treatment of chronic pain, offering both traditional and innovative therapies. The region’s market share accounts for approximately 45% of the total chronic pain market in Mexico, driven by its large population and increased healthcare spending. The high demand for advanced pain management solutions is supported by the city’s growing aging population, sedentary lifestyle trends, and increasing incidence of chronic conditions like arthritis and neuropathic pain. Additionally, the expanding availability of healthcare services, including telemedicine and pain management specialists, continues to foster market growth. With better access to cutting-edge treatments and increased awareness among the population, Mexico City is expected to maintain its leading position in the chronic pain management market.

Monterrey and Guadalajara

Monterrey, the capital of Nuevo León, represents a growing segment of the chronic pain market, with a market share of around 30%. Known for its industrial and economic significance, Monterrey has a robust healthcare system, catering to a wide range of pain management needs. The region’s healthcare infrastructure continues to evolve with private clinics and advanced pain management centers providing high-quality care. As Monterrey’s population grows, so does the demand for specialized services to treat conditions such as chronic back pain, arthritis, and cancer pain, further contributing to the expansion of the chronic pain market. The region’s rapid economic growth has also increased disposable income, enabling more residents to seek private healthcare options for pain management.

In contrast, Guadalajara, the capital of Jalisco, holds approximately 25% of the chronic pain market share. Guadalajara’s healthcare system has seen significant improvements, driven by both public and private healthcare institutions that cater to the growing number of chronic pain patients. The region’s focus on accessible healthcare services and affordable treatments is increasing demand for pain management therapies, particularly in rural areas surrounding the city. The prevalence of chronic pain conditions, including migraines and neuropathic pain, has spurred the growth of specialized clinics offering innovative treatments. Additionally, government initiatives aimed at improving healthcare access and increasing awareness about chronic pain management further bolster the region’s market potential. With an emphasis on patient-centered care and expanding healthcare facilities, Guadalajara is poised for sustained growth in the chronic pain market.

Key Player Analysis

Abbott Laboratories
Pfizer Inc.
Eli Lilly & Company
Cara Therapeutics
Chattem (Sanofi)
Endo International plc
Merck & Co. Inc.
F. Hoffmann-La Roche AG
Menarini Group

Competitive Analysis

The Mexico chronic pain market is highly competitive, with key players continually innovating and expanding their product portfolios. Leading companies in the market include Abbott Laboratories, Pfizer Inc., Eli Lilly & Company, Cara Therapeutics, Chattem (Sanofi), Endo International plc, Merck & Co. Inc., F. Hoffmann-La Roche AG, and Menarini Group. Leading companies compete by offering a wide range of pain management solutions, including opioids, NSAIDs, anticonvulsants, and antidepressants. Key strategies for market dominance include expanding product portfolios, improving the accessibility of treatments, and investing in the development of novel therapies, particularly for complex conditions such as neuropathic pain and cancer-related pain. In addition to pharmaceutical solutions, companies are focusing on integrating digital health tools, such as telemedicine and virtual pain management platforms, to improve patient access to treatments, especially in underserved regions. Regulatory challenges, such as strict opioid control and reimbursement limitations, add to the competitive dynamics, requiring companies to navigate complex policies while introducing alternative treatment options. To remain competitive, companies are also forming strategic partnerships with local healthcare providers to enhance distribution networks and reach more patients. With a growing awareness of chronic pain and increased healthcare access, the market is expected to see increased investment in both research and the expansion of pain management services across Mexico’s major urban centers and rural areas.

Recent Developments

In July 2024, Boston Scientific Corporation announced positive five-year results for the Intracept Intraosseous Nerve Ablation System, presented at the American Society of Pain & Neuroscience (ASPN) conference in Miami Beach, Florida. The data, pooled from three clinical trials, highlight the effectiveness of the Intracept system in treating vertebrogenic low back pain, a condition caused by damage to vertebral endplates.
In April 2024, Vertex Pharmaceuticals announced significant progress in its suzetrigine pain program, an oral selective NaV1.8 pain signal inhibitor that is poised to become the first new class of medicine for acute and neuropathic pain in over two decades. Following positive Phase 3 results in January 2024, the FDA granted New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain.
In February 2024, CinCor Pharma, Inc. was acquired by AstraZeneca. Cincor is a clinical stage biopharmaceutical company based out of USA that is focused on developing novel treatments for severe hypertension and chronic kidney disease.
In January 2024, Bayer AG disclosed its plan to strengthen its pharmaceutical and consumer health businesses. This move will bolster the company’s American market presence.
In January 2024, Sanofi announced its acquisition of Inhibrx, Inc., aiming to incorporate a potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency into its pipeline.
In December 2023, Forever Cheer, a pharmaceutical company holding more than 10 global patents, selected Hong Kong as the launchpad for its innovative pain management drugs, aiming to expand its global footprint and significantly impact the healthcare industry
In August 2023, MOBE and Override, digital health innovators, partnered to introduce a shared savings program for chronic pain management. This initiative focuses on providing personalized pain treatment through data analytics and behavioral health coaching, with the goal of reducing healthcare costs.

Market Concentration & Characteristics

The Mexico chronic pain market exhibits moderate concentration, with a few key players dominating the sector, though several smaller companies are also emerging with innovative therapies. The market is characterized by a mix of multinational pharmaceutical companies and local players, all competing to offer a range of pain management solutions, including opioids, NSAIDs, anticonvulsants, and antidepressants. As the demand for chronic pain treatments increases, driven by the aging population, sedentary lifestyles, and rising awareness, companies are investing heavily in research and development to provide more effective, targeted therapies. The market is shaped by a growing focus on non-opioid treatments, given the increasing concerns over opioid misuse and addiction. Additionally, the introduction of minimally invasive procedures and digital health solutions, such as telemedicine and pain management apps, is reshaping the competitive landscape. Market dynamics are also influenced by healthcare accessibility, particularly in rural areas, where challenges related to infrastructure and affordability persist. Companies are working to bridge these gaps through strategic collaborations with local healthcare providers and the expansion of telemedicine services. Overall, the market is poised for continued growth, driven by ongoing innovations, regulatory adaptations, and efforts to improve patient access to chronic pain management solutions.

Report Coverage

The research report offers an in-depth analysis based on Indication, Drug Class, Application, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

Increasing healthcare infrastructure in rural areas will improve access to chronic pain management services.
The development of combination therapies, integrating multiple drug classes, will enhance treatment efficacy.
Public awareness campaigns and patient empowerment initiatives will lead to better early diagnosis and treatment.
Advancements in genetic research may offer personalized solutions for chronic pain management in the future.
Growing adoption of private health insurance will expand access to specialized pain management services.
There will be a shift towards patient-centric care, with a focus on improving quality of life for chronic pain sufferers.
Innovations in over-the-counter pain relief products will cater to the growing demand for accessible treatments.
The rise of mobile health apps and wearables will enable better monitoring and management of chronic pain.
Increasing focus on mental health support for chronic pain patients will help address the psychological aspects of pain.
Expansion of public-private partnerships in healthcare will promote the availability of affordable pain management options.

CHAPTER NO. 1 : INTRODUCTION 19

1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.2. Key Benefits for Stakeholders 19

1.3. Target Audience 20

1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. CHRONIC PAIN Market Snapshot 21

2.2. MEXICO CHRONIC PAIN Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Mexico-Mexicoraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : CHRONIC PAIN MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.3. Increasing incidences of arthritis and other painful disease 25

4.3.1. Newer technique for pain management 26

4.4. Market Restraints 27

4.5. Treatment costs are high 27

4.6. Market Opportunities 28

4.7. Market Opportunity Analysis 28

4.8. Porter’s Five Forces Analysis 29

4.9. Value Chain Analysis 30

4.10. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by MEXICO 32

5.1.1. MEXICO CHRONIC PAIN Market Import Volume/Revenue, By MEXICO, 2018 – 2023 32

5.2. Export Analysis by MEXICO 33

5.2.1. MEXICO CHRONIC PAIN Market Export Volume/Revenue, By MEXICO, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by MEXICO 34

6.1.1. MEXICO CHRONIC PAIN Market Demand Volume/Revenue, By MEXICO, 2018 – 2023 34

6.2. Supply Analysis by MEXICO 35

6.2.1. MEXICO CHRONIC PAIN Market Supply Volume/Revenue, By MEXICO, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by MEXICO 36

7.1.1. MEXICO CHRONIC PAIN Market Production Volume/Revenue, By MEXICO, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Indication 37

8.1.1. MEXICO CHRONIC PAIN Market Price, By Indication, 2018 – 2023 37

8.1.2. MEXICO Indication Market Price, By Indication, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. MEXICO CHRONIC PAIN Market: Company Market Share, by Volume, 2023 40

11.1.2. MEXICO CHRONIC PAIN Market: Company Market Share, by Revenue, 2023 41

11.1.3. MEXICO CHRONIC PAIN Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. MEXICO CHRONIC PAIN Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. MEXICO CHRONIC PAIN Market Company Volume Market Share, 2023 43

11.3. MEXICO CHRONIC PAIN Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 44

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

MEXICO Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : CHRONIC PAIN MARKET – BY INDICATION SEGMENT ANALYSIS 49

13.1. CHRONIC PAIN Market Overview, by Indication Segment 49

13.1.1. CHRONIC PAIN Market Revenue Share, By Indication, 2023 & 2032 50

13.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Indication 51

13.1.3. Incremental Revenue Growth Opportunity, by Indication, 2024 – 2032 51

13.1.4. CHRONIC PAIN Market Revenue, By Indication, 2018, 2023, 2027 & 2032 52

13.2. Neuropathic Pain 53

13.3. Arthritis pain 54

13.4. Chronic Back pain 55

13.5. Cancer Pain 56

13.6. Migraine 57

CHAPTER NO. 14 : CHRONIC PAIN MARKET – BY DRUG CLASS SEGMENT ANALYSIS 58

14.1. CHRONIC PAIN Market Overview, by Drug Class Segment 58

14.1.1. CHRONIC PAIN Market Revenue Share, By Drug Class , 2023 & 2032 59

14.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Drug Class 60

14.1.3. Incremental Revenue Growth Opportunity, by Drug Class , 2024 – 2032 60

14.1.4. CHRONIC PAIN Market Revenue, By Drug Class , 2018, 2023, 2027 & 2032 61

14.2. Opiods 62

14.3. Non steroidal 63

14.4. Anticonvulsants 64

14.5. Antidepressants: 65

14.6. Drug Class 5 66

CHAPTER NO. 15 : CHRONIC PAIN MARKET – BY APPLICATION ANALYSIS 67

15.1. CHRONIC PAIN Market Overview, by Application 67

15.1.1. CHRONIC PAIN Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. CHRONIC PAIN Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. CHRONIC PAIN Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Musculoskeletal 71

15.3. Neuropathy 72

15.4. Oncology 73

15.5. Others 74

CHAPTER NO. 16 : CHRONIC PAIN MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 75

16.1. CHRONIC PAIN Market Overview, by Distribution Channel Segment 75

16.1.1. CHRONIC PAIN Market Revenue Share, By Distribution Channel, 2023 & 2032 76

16.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Distribution Channel 77

16.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 77

16.1.4. CHRONIC PAIN Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 78

16.2. Hospital Pharmacies 79

16.3. Retail Pharmacies 80

16.4. Others 81

CHAPTER NO. 17 : CHRONIC PAIN MARKET – MEXICO ANALYSIS 82

17.1. Indication 82

17.1.1. MEXICO CHRONIC PAIN Market Revenue, By Indication, 2018 – 2023 (USD Million) 82

17.2. MEXICO CHRONIC PAIN Market Revenue, By Indication, 2024 – 2032 (USD Million) 82

17.3. Drug Class 83

17.3.1. MEXICO CHRONIC PAIN Market Revenue, By Drug Class , 2018 – 2023 (USD Million) 83

17.3.2. MEXICO CHRONIC PAIN Market Revenue, By Drug Class , 2024 – 2032 (USD Million) 83

17.4. End-user 84

17.4.1. MEXICO CHRONIC PAIN Market Revenue, By End-user, 2018 – 2023 (USD Million) 84

17.4.2. MEXICO CHRONIC PAIN Market Revenue, By End-user, 2024 – 2032 (USD Million) 84

17.5. Technology 85

17.5.1. MEXICO CHRONIC PAIN Market Revenue, By Technology, 2018 – 2023 (USD Million) 85

17.5.2. MEXICO CHRONIC PAIN Market Revenue, By Technology, 2024 – 2032 (USD Million) 85

17.6. Distribution Channel 86

17.6.1. MEXICO CHRONIC PAIN Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 86

17.6.2. MEXICO CHRONIC PAIN Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 86

CHAPTER NO. 18 : COMPANY PROFILES 87

18.1. Abbott Laboratories 87

18.1.1. Company Overview 87

18.1.2. Product Portfolio 87

18.1.3. Swot Analysis 87

18.2. Business Strategy 88

18.3. Financial Overview 88

18.4. Pfizer Inc. 89

18.5. Eli Lilly & Company 89

18.6. Cara Therapeutics 89

18.7. Chattem (Sanofi) 89

18.8. Endo International plc 89

18.9. Merck & Co. Inc. 89

18.10. F. Hoffmann-La Roche AG. 89

18.11. Menarini Group. 89

18.12. Company 11 89

18.13. Company 12 89

18.14. Company 13 89

18.15. Company 14 89

List of Figures

FIG NO. 1. MEXICO CHRONIC PAIN Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for MEXICO CHRONIC PAIN Market 29

FIG NO. 3. Value Chain Analysis for MEXICO CHRONIC PAIN Market 30

FIG NO. 4. MEXICO CHRONIC PAIN Market Import Volume/Revenue, By MEXICO, 2018 – 2023 32

FIG NO. 5. MEXICO CHRONIC PAIN Market Export Volume/Revenue, By MEXICO, 2018 – 2023 33

FIG NO. 6. MEXICO CHRONIC PAIN Market Demand Volume/Revenue, By MEXICO, 2018 – 2023 34

FIG NO. 7. MEXICO CHRONIC PAIN Market Supply Volume/Revenue, By MEXICO, 2018 – 2023 35

FIG NO. 8. MEXICO CHRONIC PAIN Market Production Volume/Revenue, By MEXICO, 2018 – 2023 36

FIG NO. 9. MEXICO CHRONIC PAIN Market Price, By Indication, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. CHRONIC PAIN Market – Company Volume Market Share, 2023 43

FIG NO. 18. CHRONIC PAIN Market – Company Revenue Market Share, 2023 44

FIG NO. 19. CHRONIC PAIN Market Revenue Share, By Indication, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Indication 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Indication, 2024 – 2032 51

FIG NO. 22. CHRONIC PAIN Market Revenue, By Indication, 2018, 2023, 2027 & 2032 52

FIG NO. 23. MEXICO CHRONIC PAIN Market for Neuropathic Pain, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. MEXICO CHRONIC PAIN Market for Arthritis pain, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. MEXICO CHRONIC PAIN Market for Chronic Back pain , Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. MEXICO CHRONIC PAIN Market for Cancer Pain, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. MEXICO CHRONIC PAIN Market for Migraine, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. CHRONIC PAIN Market Revenue Share, By Drug Class , 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Drug Class 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Drug Class , 2024 – 2032 60

FIG NO. 31. CHRONIC PAIN Market Revenue, By Drug Class , 2018, 2023, 2027 & 2032 61

FIG NO. 32. MEXICO CHRONIC PAIN Market for Opiods, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. MEXICO CHRONIC PAIN Market for Non steroidal , Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. MEXICO CHRONIC PAIN Market for Anticonvulsants, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. MEXICO CHRONIC PAIN Market for Antidepressants:, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. MEXICO CHRONIC PAIN Market for Drug Class 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. CHRONIC PAIN Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. CHRONIC PAIN Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. MEXICO CHRONIC PAIN Market for Musculoskeletal, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. MEXICO CHRONIC PAIN Market for Neuropathy, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. MEXICO CHRONIC PAIN Market for Oncology, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. MEXICO CHRONIC PAIN Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. MEXICO CHRONIC PAIN Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. CHRONIC PAIN Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. CHRONIC PAIN Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. MEXICO CHRONIC PAIN Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. MEXICO CHRONIC PAIN Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. MEXICO CHRONIC PAIN Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. CHRONIC PAIN Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. CHRONIC PAIN Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. MEXICO CHRONIC PAIN Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. MEXICO CHRONIC PAIN Market for Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. MEXICO CHRONIC PAIN Market for Others, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. MEXICO CHRONIC PAIN Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. MEXICO CHRONIC PAIN Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : MEXICO CHRONIC PAIN Market: Snapshot 18

TABLE NO. 2. : Drivers for the CHRONIC PAIN Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the CHRONIC PAIN Market: Impact Analysis 24

TABLE NO. 4. : MEXICO CHRONIC PAIN Market Revenue, By Indication, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : MEXICO CHRONIC PAIN Market Revenue, By Indication, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : MEXICO CHRONIC PAIN Market Revenue, By Indication, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : MEXICO CHRONIC PAIN Market Revenue, By Drug Class , 2018 – 2023 (USD Million) 90

TABLE NO. 9. : MEXICO CHRONIC PAIN Market Revenue, By Drug Class , 2024 – 2032 (USD Million) 90

TABLE NO. 10. : MEXICO CHRONIC PAIN Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : MEXICO CHRONIC PAIN Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : MEXICO CHRONIC PAIN Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : MEXICO CHRONIC PAIN Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : MEXICO CHRONIC PAIN Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : MEXICO CHRONIC PAIN Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 9

Frequently Asked Questions:

What is the current size of the Mexico Chronic Pain market?

The Mexico chronic pain market was valued at USD 2,265.54 million in 2023 and is projected to reach USD 3,273.41 million by 2032, growing at a compound annual growth rate (CAGR) of 3.97%.

What factors are driving the growth of the Mexico Chronic Pain market?

The market is driven by the increasing prevalence of chronic conditions such as arthritis, neuropathy, and cancer-related pain, along with the aging population. Growing awareness about pain management therapies, advancements in treatment options, and the adoption of telemedicine and digital health solutions also contribute to market growth.

What are the key segments within the Mexico Chronic Pain market?

The market is segmented by:
• Indication: Neuropathic pain, arthritis pain, chronic back pain, cancer pain, and migraine.
• Drug Class: Opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and other emerging drug classes.
• Application: Musculoskeletal, neuropathy, oncology, and others.
• Distribution Channel: Hospital pharmacies, retail pharmacies, and others.

Who are the major players in the Mexico Chronic Pain market?

Key players include Abbott Laboratories, Pfizer Inc., Eli Lilly & Company, Cara Therapeutics, Chattem (Sanofi), Endo International plc, Merck & Co. Inc., F. Hoffmann-La Roche AG, and Menarini Group.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –